Although there are still side effects and weight fluctuations to consider, the results overall have been overwhelmingly positive and have caused great enthusiasm among doctors, patients, and investors
The additional steps are not difficult, but they require attention to detail
Further information on symptoms and thresholds is available from the NHS (nhs.uk) and Diabetes UK (diabetes.org.uk)
Glucagon-like peptide 1 receptor agonists for type 2 diabetes, Diabetes Spectrum (2017) With Trulicity, patients may be able to lose some weight, Eli Lilly Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11), Diabetes Care (2021) Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial, Lancet Diabetes Endocrinology (2017) Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial, Lancet (2014) Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3), Diabetes Care (2014) Mounjaro prescribing information, Eli Lilly Beyond glycemia: Comparing tirzepatide to GLP-1 analogues, Reviews in Endocrine and Metabolic Disorders (2023) Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial, Lancet Diabetes Endocrinology (2022) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
Steroids 78 , 12731280 (2013)
Licensed options include
